Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 6/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 6/20 | 0.35 |
| ▸ | TNKS | O95271 | 4/20 | 0.35 |
| ▸ | PTAFR | P25105 | 2/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25448183 | 0.92 | P2RX7 (0.35) | P2RX7TNKS2TNKSPTAFRGABRA1 | |
| SCHEMBL23927139 | 0.91 | GABRA1 (0.34) | P2RX7TNKS2TNKSPTAFRGABRA1 | |
| SCHEMBL30201793 | 0.91 | GABRA1 (0.34) | P2RX7TNKS2TNKSPTAFRGABRA1 | |
| SCHEMBL23927115 | 0.90 | P2RX7 (0.39) | P2RX7TNKS2TNKSPTAFRGABRA1 | |
| SCHEMBL23927133 | 0.90 | P2RX7 (0.41) | P2RX7TNKS2TNKSPTAFRGABRA1 | |
| SCHEMBL30201949 | 0.88 | PTAFR (0.42) | P2RX7TNKS2TNKSPTAFRGABRA1 | |
| SCHEMBL23927148 | 0.88 | PTAFR (0.42) | P2RX7TNKS2TNKSPTAFRGABRA1 | |
| SCHEMBL23927170 | 0.87 | P2RX7 (0.35) | P2RX7TNKS2TNKSPTAFRGABRA1 | |
| SCHEMBL30201991 | 0.87 | P2RX7 (0.35) | P2RX7TNKS2TNKSPTAFRGABRA1 | |
| SCHEMBL23927189 | 0.84 | TNKS2 (0.37) | P2RX7TNKS2TNKSPTAFRGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4139310-B1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | HOFFMANN LA ROCHE (CH) | 2024-03-27 | — | — | EP | claimed |
| US-20230141603-A1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | claimed |
| EP-4139310-A1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | F. Hoffmann-La Roche AG (CH) | 2023-03-01 | — | — | EP | claimed |
| EP-3901155-A1 | NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | claimed |
| EP-4139310-B1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | HOFFMANN LA ROCHE (CH) | 2024-03-27 | — | — | EP | disclosed |
| US-20230141603-A1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230141603-A1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230141603-A1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4139310-A1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | F. Hoffmann-La Roche AG (CH) | 2023-03-01 | — | — | EP | disclosed |
| CN-115667262-A | Benzodiazepine derivatives as GABAA γ 1PAM | 豪夫迈·罗氏有限公司 | 2023-01-31 | — | — | CN | disclosed |
| WO-2021213952-A1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | F. HOFFMANN-LA ROCHE AG (CH) | 2021-10-28 | — | — | WO | disclosed |
| EP-3901155-A1 | NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| EP-3901155-A1 | NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141603-A1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | GABRA1, GABRB1, GABRB3 | P2RX7 303/4885TNKS2 3705/4885TNKS 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.